Report Detail

Request for Sample of this report

Pharma & Healthcare Global VMAT2 Inhibitors Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

  • RnM4517211
    • |
  • 27 February, 2023
    • |
  • Global
    • |
  • 105 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global VMAT2 Inhibitors market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington’s disease.
This report is a detailed and comprehensive analysis for global VMAT2 Inhibitors market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global VMAT2 Inhibitors market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global VMAT2 Inhibitors market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global VMAT2 Inhibitors market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global VMAT2 Inhibitors market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for VMAT2 Inhibitors
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global VMAT2 Inhibitors market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc and Hetero, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
VMAT2 Inhibitors market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tetrabenazine
Valbenazine
Other
Market segment by Application
Huntington’s Disease
Tardive Dyskinesia
Other
Major players covered
Neurocrine Biosciences, Inc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Hikma Pharmaceuticals plc
Hetero
Bausch Health Companies Inc
Dr. Reddy's Laboratories Ltd
Piramal Pharma Solution
Lupin
Luye Pharma Group
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe VMAT2 Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of VMAT2 Inhibitors, with price, sales, revenue and global market share of VMAT2 Inhibitors from 2018 to 2023.
Chapter 3, the VMAT2 Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the VMAT2 Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and VMAT2 Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of VMAT2 Inhibitors.
Chapter 14 and 15, to describe VMAT2 Inhibitors sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of VMAT2 Inhibitors
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global VMAT2 Inhibitors Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Tetrabenazine
    • 1.3.3 Valbenazine
    • 1.3.4 Other
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global VMAT2 Inhibitors Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Huntington’s Disease
    • 1.4.3 Tardive Dyskinesia
    • 1.4.4 Other
  • 1.5 Global VMAT2 Inhibitors Market Size & Forecast
    • 1.5.1 Global VMAT2 Inhibitors Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global VMAT2 Inhibitors Sales Quantity (2018-2029)
    • 1.5.3 Global VMAT2 Inhibitors Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Neurocrine Biosciences, Inc
    • 2.1.1 Neurocrine Biosciences, Inc Details
    • 2.1.2 Neurocrine Biosciences, Inc Major Business
    • 2.1.3 Neurocrine Biosciences, Inc VMAT2 Inhibitors Product and Services
    • 2.1.4 Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Neurocrine Biosciences, Inc Recent Developments/Updates
  • 2.2 Teva Pharmaceutical Industries Ltd
    • 2.2.1 Teva Pharmaceutical Industries Ltd Details
    • 2.2.2 Teva Pharmaceutical Industries Ltd Major Business
    • 2.2.3 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product and Services
    • 2.2.4 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
  • 2.3 Sun Pharmaceutical Industries Ltd
    • 2.3.1 Sun Pharmaceutical Industries Ltd Details
    • 2.3.2 Sun Pharmaceutical Industries Ltd Major Business
    • 2.3.3 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product and Services
    • 2.3.4 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
  • 2.4 Hikma Pharmaceuticals plc
    • 2.4.1 Hikma Pharmaceuticals plc Details
    • 2.4.2 Hikma Pharmaceuticals plc Major Business
    • 2.4.3 Hikma Pharmaceuticals plc VMAT2 Inhibitors Product and Services
    • 2.4.4 Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates
  • 2.5 Hetero
    • 2.5.1 Hetero Details
    • 2.5.2 Hetero Major Business
    • 2.5.3 Hetero VMAT2 Inhibitors Product and Services
    • 2.5.4 Hetero VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Hetero Recent Developments/Updates
  • 2.6 Bausch Health Companies Inc
    • 2.6.1 Bausch Health Companies Inc Details
    • 2.6.2 Bausch Health Companies Inc Major Business
    • 2.6.3 Bausch Health Companies Inc VMAT2 Inhibitors Product and Services
    • 2.6.4 Bausch Health Companies Inc VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Bausch Health Companies Inc Recent Developments/Updates
  • 2.7 Dr. Reddy's Laboratories Ltd
    • 2.7.1 Dr. Reddy's Laboratories Ltd Details
    • 2.7.2 Dr. Reddy's Laboratories Ltd Major Business
    • 2.7.3 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product and Services
    • 2.7.4 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Dr. Reddy's Laboratories Ltd Recent Developments/Updates
  • 2.8 Piramal Pharma Solution
    • 2.8.1 Piramal Pharma Solution Details
    • 2.8.2 Piramal Pharma Solution Major Business
    • 2.8.3 Piramal Pharma Solution VMAT2 Inhibitors Product and Services
    • 2.8.4 Piramal Pharma Solution VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Piramal Pharma Solution Recent Developments/Updates
  • 2.9 Lupin
    • 2.9.1 Lupin Details
    • 2.9.2 Lupin Major Business
    • 2.9.3 Lupin VMAT2 Inhibitors Product and Services
    • 2.9.4 Lupin VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Lupin Recent Developments/Updates
  • 2.10 Luye Pharma Group
    • 2.10.1 Luye Pharma Group Details
    • 2.10.2 Luye Pharma Group Major Business
    • 2.10.3 Luye Pharma Group VMAT2 Inhibitors Product and Services
    • 2.10.4 Luye Pharma Group VMAT2 Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Luye Pharma Group Recent Developments/Updates

3 Competitive Environment: VMAT2 Inhibitors by Manufacturer

  • 3.1 Global VMAT2 Inhibitors Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global VMAT2 Inhibitors Revenue by Manufacturer (2018-2023)
  • 3.3 Global VMAT2 Inhibitors Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of VMAT2 Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 VMAT2 Inhibitors Manufacturer Market Share in 2022
    • 3.4.2 Top 6 VMAT2 Inhibitors Manufacturer Market Share in 2022
  • 3.5 VMAT2 Inhibitors Market: Overall Company Footprint Analysis
    • 3.5.1 VMAT2 Inhibitors Market: Region Footprint
    • 3.5.2 VMAT2 Inhibitors Market: Company Product Type Footprint
    • 3.5.3 VMAT2 Inhibitors Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global VMAT2 Inhibitors Market Size by Region
    • 4.1.1 Global VMAT2 Inhibitors Sales Quantity by Region (2018-2029)
    • 4.1.2 Global VMAT2 Inhibitors Consumption Value by Region (2018-2029)
    • 4.1.3 Global VMAT2 Inhibitors Average Price by Region (2018-2029)
  • 4.2 North America VMAT2 Inhibitors Consumption Value (2018-2029)
  • 4.3 Europe VMAT2 Inhibitors Consumption Value (2018-2029)
  • 4.4 Asia-Pacific VMAT2 Inhibitors Consumption Value (2018-2029)
  • 4.5 South America VMAT2 Inhibitors Consumption Value (2018-2029)
  • 4.6 Middle East and Africa VMAT2 Inhibitors Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 5.2 Global VMAT2 Inhibitors Consumption Value by Type (2018-2029)
  • 5.3 Global VMAT2 Inhibitors Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 6.2 Global VMAT2 Inhibitors Consumption Value by Application (2018-2029)
  • 6.3 Global VMAT2 Inhibitors Average Price by Application (2018-2029)

7 North America

  • 7.1 North America VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 7.2 North America VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 7.3 North America VMAT2 Inhibitors Market Size by Country
    • 7.3.1 North America VMAT2 Inhibitors Sales Quantity by Country (2018-2029)
    • 7.3.2 North America VMAT2 Inhibitors Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 8.2 Europe VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 8.3 Europe VMAT2 Inhibitors Market Size by Country
    • 8.3.1 Europe VMAT2 Inhibitors Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe VMAT2 Inhibitors Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific VMAT2 Inhibitors Market Size by Region
    • 9.3.1 Asia-Pacific VMAT2 Inhibitors Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific VMAT2 Inhibitors Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 10.2 South America VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 10.3 South America VMAT2 Inhibitors Market Size by Country
    • 10.3.1 South America VMAT2 Inhibitors Sales Quantity by Country (2018-2029)
    • 10.3.2 South America VMAT2 Inhibitors Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa VMAT2 Inhibitors Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa VMAT2 Inhibitors Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa VMAT2 Inhibitors Market Size by Country
    • 11.3.1 Middle East & Africa VMAT2 Inhibitors Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa VMAT2 Inhibitors Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 VMAT2 Inhibitors Market Drivers
  • 12.2 VMAT2 Inhibitors Market Restraints
  • 12.3 VMAT2 Inhibitors Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of VMAT2 Inhibitors and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of VMAT2 Inhibitors
  • 13.3 VMAT2 Inhibitors Production Process
  • 13.4 VMAT2 Inhibitors Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 VMAT2 Inhibitors Typical Distributors
  • 14.3 VMAT2 Inhibitors Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on VMAT2 Inhibitors. Industry analysis & Market Report on VMAT2 Inhibitors is a syndicated market report, published as Global VMAT2 Inhibitors Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of VMAT2 Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,777.04
    		4,165.56
    		5,554.08
    		3,246.84
    		4,870.26
    		6,493.68
    		535,084.80
    		802,627.20
    		1,070,169.60
    		290,440.80
    		435,661.20
    		580,881.60
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo